Author: [AUTHOR] Published on 8/1/2020 12:00:00 AM
Tore B. Stage, PhD, Associate Professor, University of Southern Denmark, Odense, Denmark
Dr. Stage's PhD supervisor and mentor, Kim Brosen, told him about ASCPT membership and the Annual Meeting. A cursory glance at the Meeting’s program convinced Dr. Stage to join the Society and start attending the Annual Meeting. He was drawn by the high quality of the science. Reading the high‐quality papers from the journal family also inspired him to take the next step and get involved with ASCPT.
The Annual Meeting and the journal family are Dr. Stage’s favorite aspect of ASCPT membership. He enjoys attending the Annual Meeting because it is an excellent opportunity to catch up with colleagues and friends from the United States. He also enjoys the combination of the academic, regulatory, and industrial fields, which is quite unique. In his newly established work group, attending the Annual Meeting is a priority.
Membership in ASCPT has benefitted Dr. Stage’s career. He counts himself lucky to have received a Presidential Trainee Award as well as being designated the Jason Morrow, MD, Presidential Trainee. These awards boosted his CV, and he believes that they have helped him obtain substantial funding and pursue a career in academia. He believes that through the journal family ASCPT has also helped lead the field—specifically through CPT . He believes the premier journal allows the Society and its leadership to help shape and direct the field.
Dr. Stage joined the Society early in his career and he encourages the younger generation of scientists to follow his example. He advises them to volunteer for ASCPT activities and to attend webinars and the Annual Meeting. He points out that “there are plenty of opportunities for early‐career scientists.”
Currently, Dr. Stage feels that he is blessed by a research infrastructure that allows him and his team to perform both in vitro –based research and clinical studies. The ambition of the work group is to contribute with research within translational pharmacology. The group seeks to determine impact of efflux transporters on chemotherapy disposition and toxicity, particularly in the peripheral nervous system. Additionally, they are trying to assess the impact of low‐grade inflammation on drug metabolism and transport. Finally, they are continuing their work with isoxazolyl penicillins. They showed that a member of this group, dicloxacillin, is a potent inducer of CYP enzymes and that drug–drug interactions with this penicillin have direct clinical impact as it reduces the efficacy of warfarin and leads to higher risk of stroke.
Dr. Stage has been a member of ASCPT since 2015.